📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 15:21
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Hikal Board Reshuffle: Jai Hiremath Steps Down as Exec Chairman; Anish Swadi Appointed CEO-Animal Health
Hikal announced major board leadership changes effective October 01, 2026. Founder Mr. Jai Hiremath has completed his term as Executive Chairman and has been appointed Chairman Emeritus for a 5-year period without board or officer status. Concurrently, Mrs. Sugandha Hiremath resigned as Non-Executive Director effective September 30, 2026, citing personal commitments. Additionally, Mr. Anish Swadi was elevated to CEO - Animal Health and Specialty Ingredients, a key strategic growth vertical for the company.
Confidence: HIGH
What changedExecutive Chairman Jai Hiremath stepped down to become Chairman Emeritus, Sugandha Hiremath exited the Board, and Anish Swadi took charge as CEO of Animal Health and Specialty Ingredients.
Why it mattersRepresents a generational/governance transition at the promoter level while formalizing executive leadership over the high-growth Animal Health and CDMO portfolio.
Chairman Emeritus tenure: 5 yearsEffective date of changes: October 01, 2026Mrs. Sugandha Hiremath board tenure: since 1992
📅 Short termGovernance changes are orderly; markets will watch for announcements regarding a new Board Chairperson or further executive realignments.
📈 Long termThe elevation of dedicated leadership for the Animal Health segment aligns with the company's stated mid-to-long term turnaround and margin expansion strategy.
⚠ Risk flags
- Loss of long-standing Board leadership during a period of turnaround (TTM PAT at Rs -34 Cr)
- Execution risk in scaling the Animal Health segment
Key Highlights
Cessation of Mr. Jai Hiremath's term as Executive Chairman effective October 01, 2026
Appointment of Mr. Jai Hiremath as Chairman Emeritus for a 5-year period effective October 01, 2026
Resignation of Non-Executive Director Mrs. Sugandha Hiremath effective September 30, 2026
Appointment of Mr. Anish Swadi as CEO - Animal Health and Specialty Ingredients effective October 01, 2026
👀 What to Watch
Track the succession at the Board's top executive level and monitor performance execution in the Animal Health vertical, which is a stated primary growth driver.
Hikal Board Reshuffle: Jai Hiremath Steps Down as Exec Chairman; Anish Swadi Appointed CEO-Animal Health
Hikal announced major board leadership changes effective October 01, 2026. Founder Mr. Jai Hiremath has completed his term as Executive Chairman and has been appointed Chairman Emeritus for a 5-year period without board or officer status. Concurrently, Mrs. Sugandha Hiremath resigned as Non-Executive Director effective September 30, 2026, citing personal commitments. Additionally, Mr. Anish Swadi was elevated to CEO - Animal Health and Specialty Ingredients, a key strategic growth vertical for the company.
Confidence: HIGH
What changedExecutive Chairman Jai Hiremath stepped down to become Chairman Emeritus, Sugandha Hiremath exited the Board, and Anish Swadi took charge as CEO of Animal Health and Specialty Ingredients.
Why it mattersRepresents a generational/governance transition at the promoter level while formalizing executive leadership over the high-growth Animal Health and CDMO portfolio.
Chairman Emeritus tenure: 5 yearsEffective date of changes: October 01, 2026Mrs. Sugandha Hiremath board tenure: since 1992
📅 Short termGovernance changes are orderly; markets will watch for announcements regarding a new Board Chairperson or further executive realignments.
📈 Long termThe elevation of dedicated leadership for the Animal Health segment aligns with the company's stated mid-to-long term turnaround and margin expansion strategy.
⚠ Risk flags
- Loss of long-standing Board leadership during a period of turnaround (TTM PAT at Rs -34 Cr)
- Execution risk in scaling the Animal Health segment
Key Highlights
Cessation of Mr. Jai Hiremath's term as Executive Chairman effective October 01, 2026
Appointment of Mr. Jai Hiremath as Chairman Emeritus for a 5-year period effective October 01, 2026
Resignation of Non-Executive Director Mrs. Sugandha Hiremath effective September 30, 2026
Appointment of Mr. Anish Swadi as CEO - Animal Health and Specialty Ingredients effective October 01, 2026
👀 What to Watch
Track the succession at the Board's top executive level and monitor performance execution in the Animal Health vertical, which is a stated primary growth driver.
Hikal Shareholders Approve Sameer Hiremath as CMD for 5-Year Term; Reaffirms Panoli Expansion
Hikal Limited announced that shareholders approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a 5-year term from October 1, 2026, to September 30, 2031. Shareholders at the 38th AGM also approved the FY26 audited accounts and a final dividend of Rs 0.40 per share. Additionally, the company highlighted the commercial commencement of personal care manufacturing at its new Panoli, Gujarat cGMP facility, marking an entry into beauty and personal care. This leadership continuity comes amid challenging operational performance, with Hikal reporting a net loss of Rs 34 Cr over the TTM period.
Confidence: HIGH
What changedShareholders formally approved Sameer Hiremath as Chairman & MD for five years through September 2031 and approved a Rs 0.40/share final dividend.
Why it mattersProvides leadership stability and confirms commercialization of the Panoli facility, supporting strategic diversification into personal care and specialty chemicals to offset weak agrochem pricing.
CMD Tenure: 5 years (Oct 1, 2026 to Sep 30, 2031)Final Dividend per share: Rs 0.40TTM Net Loss: Rs -34 CrAnnual General Meeting: 38th AGM
📅 Short termNeutral to mildly positive as leadership succession uncertainty is settled and AGM approvals (including dividend) are formalized.
📈 Long termExecution at the Panoli facility will be critical to turn around profitability, given Hikal's FY26 net loss of Rs 49.3 Cr and low ROCE of 4.0%.
⚠ Risk flags
- Ongoing operational drag reflected in TTM net losses of Rs 34 Cr
- High product concentration in Gabapentin and top crop protection molecules
Key Highlights
Appointment of Sameer Hiremath as Chairman & Managing Director approved for a 5-year tenure (Oct 1, 2026 to Sep 30, 2031)
Shareholders approved a final dividend of Rs 0.40 per share for FY2025-26
Commenced commercial production of Personal Care products at new cGMP multipurpose facility in Panoli, Gujarat
Re-appointment of Mr. Sarangan Suresh as Executive Director approved at the 38th AGM
Company awarded the EcoVadis Gold Medal rating, ranking in top 5% of companies globally for sustainability
👀 What to Watch
Track capacity ramp-up and revenue contribution from the newly commissioned Panoli personal care facility in upcoming quarterly results, alongside profitability recovery following FY26 net losses.
Hikal Enters Personal Care: Starts Commercial Production at cGMP Panoli Facility
Hikal Limited has commenced commercial production for its new Personal Care business following the commissioning of a repurposed cGMP multipurpose facility at Panoli, Gujarat. The initial portfolio focuses on skin care and second-generation UV filters, with initial production batches manufactured and validated with customers. The company aims to build this into a high-value growth platform alongside its existing Pharma, Crop Protection, and Animal Health segments. This strategic entry comes as Hikal works to rebound from a challenging TTM net loss of Rs -34 crore on TTM revenue of Rs 1,734 crore.
Confidence: HIGH
What changedHikal officially initiated commercial-scale production and completed initial batch validation for its new personal care vertical at the repurposed Panoli site.
Why it mattersProvides a new diversification avenue away from the margin-pressured crop protection and API businesses, potentially boosting profitability given the higher-margin profile of specialty personal care ingredients.
Announcement Date: September 22, 2026EcoVadis Score: 84/100EcoVadis Percentile Ranking: 97th percentileCapex or Capacity Added: not disclosed
📅 Short termPositive sentiment driver as the company successfully achieves operational commissioning of a new business vertical.
📈 Long termCould structurally improve product mix and margins over the coming years if customer audits convert into stable commercial off-take contracts.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Commercial uptake and scale-up timelines remain dependent on customer qualification approvals.
- Financial investment amount and expected revenue contribution are not disclosed.
Key Highlights
Commissioned cGMP-compliant multipurpose manufacturing facility at Panoli, Gujarat for personal care.
Repurposed existing manufacturing asset to produce second-generation UV filters for the global beauty and skin care market.
First commercial production batches successfully manufactured and samples validated with global customers.
Follows receipt of EcoVadis Gold Medal rating with a score of 84/100, ranking in the 97th percentile globally.
👀 What to Watch
Track the upcoming quarterly revenue disclosures to see how quickly personal care sales ramp up and whether capacity utilization figures or revenue targets for Panoli are provided.
Hikal Appoints Sameer Hiremath as Chairman & MD for a 5-Year Term From Oct 1, 2026
Hikal Limited's Board of Directors has approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a 5-year tenure effective October 1, 2026, to September 30, 2031, subject to shareholder approval. Mr. Hiremath currently serves as Vice Chairman and Managing Director and has been with the company for nearly three decades. The transition ensures executive continuity for the bulk drugs and CDMO company (market cap Rs 2,600 Cr), which is currently working through operational turnarounds following a TTM net loss of Rs 34 Cr.
Confidence: HIGH
What changedElevation of Vice Chairman & MD Sameer Hiremath to the consolidated role of Chairman and Managing Director starting October 1, 2026.
Why it mattersEnsures promoter-led leadership stability and strategic continuity across Hikal's manufacturing, CDMO pipeline, and business development initiatives.
Term length: 5 (Five) yearsTenure start date: October 01, 2026Tenure end date: September 30, 2031
📅 Short termNeutral reaction expected since Mr. Hiremath is already an established executive leader within the company.
📈 Long termProvides governance and operational continuity as Hikal seeks margin recovery across its pharma and crop protection portfolios.
⚠ Risk flags
- Subject to shareholder approval at the AGM
- Promoter family succession
Key Highlights
Appointment of Mr. Sameer Hiremath as Chairman and Managing Director approved for a 5-year period.
Term is effective from October 01, 2026, through September 30, 2031.
Appointment is subject to the approval of shareholders at the upcoming Annual General Meeting.
Mr. Hiremath brings nearly 30 years of association with Hikal, currently serving as Vice Chairman & MD.
👀 What to Watch
Track shareholder voting on the appointment at the ensuing AGM and monitor operational execution in the CDMO and API business units amid ongoing turnaround efforts.
Hikal Targets US FDA Re-inspection by FY27-End; Rs 900 Cr Capex Invested Over 4 Years
Hikal reported Q1 FY27 revenue of ₹403 cr with an EBITDA margin of 9.2%, signaling a recovery from recent regulatory disruptions. The company is currently remediating a US FDA warning letter received in August 2025 and expects a re-inspection by the end of the current fiscal year. Management highlighted a total investment of ₹900 cr over the last four years, with ₹600 cr specifically for growth projects. The Animal Health segment is projected to reach ₹400 cr in revenue by FY30, while a new Personal Care line has recently commenced commercial production.
Confidence: HIGH
What changedThe company has transitioned from regulatory-led disruption to execution-led growth, commissioning a new Personal Care manufacturing line and a pilot plant at Panoli.
Why it mattersResolving the US FDA warning letter is essential for Hikal to normalize its pharma operations and accelerate its CDMO pipeline, which has been constrained by regulatory status.
Q1 FY27 Revenue: ₹403 cr4-Year Total Capex: ₹900 crGrowth Capex vs Market Cap: ~22%EBITDA Margin: 9.2%Animal Health FY30 Target: ₹400 cr
📅 Short termThe stock may remain range-bound as the market waits for concrete progress on the US FDA re-inspection and stabilization of margins in the Crop Protection segment.
📈 Long termStructural growth is tied to the scale-up of the Animal Health and Personal Care segments and the successful de-risking of manufacturing from Bangalore to Panoli.
⚠ Risk flags
- US FDA Warning Letter remediation risk
- Pricing pressure in Crop Protection due to Chinese overcapacity
- High product concentration in Gabapentin (35-40% of pharma revenue)
Key Highlights
Targeting 6-7 DMF filings per year, a significant increase from the historical 2-3 filings
Total capex of ₹900 cr over 4 years, with ₹600 cr (approx. 22% of market cap) dedicated to growth
Animal Health business guided to reach ₹400 cr revenue by FY30
Zero customer contracts lost despite 86 audits following the US FDA warning letter
Pharma business growth projected at 18-19% CAGR once US FDA issues are resolved
👀 What to Watch
Investors should monitor the successful completion of US FDA remediation milestones and the specific timeline for the re-inspection of the Bangalore facility, which is critical for unlocking higher-margin pharma growth.
Q1 FY27 Results: Revenue at ₹403 Cr, EBITDA Margin Expands 260 bps to 9.2%
Hikal reported a 6.2% YoY revenue growth to ₹403 Cr for Q1 FY27, driven by a 15.2% recovery in the Pharmaceutical segment (₹233 Cr). While the company remains in a net loss position of ₹7 Cr, this is a significant improvement from the ₹22 Cr loss in Q1 FY26. EBITDA grew 47.4% YoY to ₹37 Cr, reflecting margin expansion despite higher input costs in the Crop Protection segment. The company is in the final stages of US FDA remediation and recently commercialized its Personal Care facility in July 2026.
Confidence: HIGH
What changedHikal is transitioning from regulatory-led disruption toward growth, evidenced by narrowing losses and a recovery in the Pharma segment despite headwinds in Crop Protection.
Why it mattersThe margin expansion and narrowing losses indicate operational stabilization after a difficult FY26 (TTM PAT of -₹49 Cr). The shift toward higher-value APIs and new segments like Personal Care are key to long-term profitability.
Q1 FY27 Revenue: ₹403 CrQ1 FY27 EBITDA Margin: 9.2%Pharma Segment Revenue: ₹233 CrNet Profit (Loss): ₹-7 CrQ1 Revenue vs TTM Revenue: 23.5%
📅 Short termThe market may view the narrowing losses and margin expansion as a sign of a turnaround, though the continued net loss and Crop Protection weakness remain concerns.
📈 Long termStructural recovery depends on successful US FDA clearance, scaling the Animal Health business, and the contribution of the new Personal Care segment to diversify revenue.
⚠ Risk flags
- Continued net losses
- US FDA regulatory uncertainty (reinspection pending)
- High input costs impacting Crop Protection margins
- High client concentration in Gabapentin (35-40% of pharma revenue)
Key Highlights
Consolidated revenue grew 6.2% YoY to ₹403 Cr, representing ~23.5% of TTM revenue.
EBITDA margins expanded by 260 bps YoY to reach 9.2%, with absolute EBITDA at ₹37 Cr.
Pharmaceutical segment revenue increased 15.2% YoY to ₹233 Cr, now contributing 58% of total revenue.
Net loss narrowed significantly to ₹7 Cr compared to a loss of ₹22 Cr in Q1 FY26.
DMF filing trajectory increased to 5-6 filings annually versus 2-3 historically.
👀 What to Watch
Monitor the timeline for the US FDA reinspection expected within FY27 and the revenue ramp-up from the newly commissioned Personal Care facility at Panoli.
Hikal Q1 FY27: Revenue Up 6% to ₹403 Cr, EBITDA Grows 47% Despite ₹7 Cr Net Loss
Hikal reported a 5.9% YoY revenue growth to ₹403 Cr for Q1 FY27, though it remains in a net loss position of ₹7 Cr, an improvement from the ₹22 Cr loss in Q1 FY26. The Pharmaceutical segment showed recovery with 15.2% revenue growth to ₹233 Cr, while the Crop Protection segment struggled with an EBIT loss of ₹6 Cr due to high input costs and subdued CDMO demand. EBITDA margins expanded by 260 bps to 9.2%, supported by a ₹9 Cr exceptional gain from labor code provision reversals. The company is in the final stages of US FDA remediation and has commissioned a new Personal Care facility at Panoli.
Confidence: HIGH
What changedHikal is transitioning from regulatory-led disruptions to a growth phase, marked by the commissioning of its Personal Care plant and the penultimate stage of US FDA remediation.
Why it mattersThe company is attempting to recover from a loss-making FY26 by shifting its mix toward higher-value APIs and diversifying into Personal Care, though Crop Protection pricing remains a significant headwind.
Q1 FY27 Revenue: ₹403 CrQ1 FY27 Net Loss: ₹7 CrEBITDA Margin: 9.2%Pharma Revenue Growth (YoY): 15.2%Annual DMF Filings Target: 5-6 unitsRevenue vs TTM Revenue: 23.5%
📅 Short termThe stock may see neutral to cautious sentiment as the company remains loss-making at the PAT level despite operational EBITDA improvement.
📈 Long termLong-term recovery is contingent on successful US FDA clearance, stabilization of Crop Protection margins, and the scale-up of the Animal Health and Personal Care businesses.
⚠ Risk flags
- Pending US FDA reinspection outcome
- High client concentration (Gabapentin 35-40% of Pharma revenue)
- Pricing pressure in Crop Protection due to global overcapacity
Key Highlights
Consolidated Revenue grew 5.9% YoY to ₹403 Cr, despite geopolitical headwinds.
EBITDA increased 47.4% YoY to ₹37 Cr, with margins improving to 9.2% from 6.6%.
Pharmaceutical segment revenue rose 15.2% YoY to ₹233 Cr, with DMF filings increasing to 5-6 annually.
Crop Protection segment reported an EBIT loss of ₹6 Cr, down from a ₹17 Cr profit in the previous year's quarter.
Exceptional income of ₹9 Cr recorded due to reversal of excess provisions for the new labor code.
👀 What to Watch
Investors should monitor the timeline for the US FDA reinspection expected in FY27 and the ramp-up of the newly commissioned Panoli facility for Personal Care revenues.
Hikal Q1 FY27: Revenue up 6% YoY to ₹402.8 Cr; Net Loss narrows to ₹7.3 Cr
Hikal reported consolidated revenue of ₹402.8 Cr for Q1 FY27, a 5.9% increase compared to ₹380.4 Cr in Q1 FY26, though it declined 22.4% sequentially from Q4 FY26. The company posted a consolidated net loss of ₹7.3 Cr, an improvement from the ₹23.1 Cr loss in the same period last year. Performance was aided by an exceptional gain of ₹8.9 Cr from salary restructuring, while the Pharma segment (₹233.3 Cr revenue) remains impacted by a 2025 USFDA warning letter. The Crop Protection segment reported an EBIT loss of ₹6.0 Cr, reflecting continued margin pressure.
Confidence: HIGH
What changedHikal has shown a year-on-year recovery in revenue and narrowing losses, though it remains in the red and saw a significant sequential drop in performance compared to Q4 FY26.
Why it mattersThe company is navigating regulatory headwinds in its Pharma business and cyclical pressure in Crop Protection; the narrowing loss suggests cost-control measures are taking effect.
Consolidated Revenue (Q1 FY27): ₹402.8 CrConsolidated Net Loss (Q1 FY27): ₹7.3 CrPharma Segment Revenue: ₹233.3 CrCrop Protection EBIT: ₹-6.0 CrExceptional Gain: ₹8.9 CrRevenue vs TTM Revenue: ~23.5%
📅 Short termThe stock may see neutral to slightly cautious sentiment as the sequential decline in revenue and continued losses offset the year-on-year improvement.
📈 Long termStructural recovery depends on clearing the USFDA warning letter and the successful scale-up of new molecules in the animal health and specialty chemicals segments.
⚠ Risk flags
- Ongoing USFDA warning letter impact on Pharma sales
- Loss-making Crop Protection segment
- Pending environmental litigation in the Supreme Court with ₹17.45 Cr potential liability
Key Highlights
Consolidated revenue grew 5.9% YoY to ₹402.8 Cr, representing ~23.5% of TTM revenue.
Pharma segment revenue increased 15.1% YoY to ₹233.3 Cr despite ongoing USFDA warning letter impacts.
Crop Protection segment reported an EBIT loss of ₹6.0 Cr compared to a profit of ₹17.3 Cr in Q1 FY26.
Exceptional gain of ₹8.9 Cr recorded due to salary restructuring and reduction in gratuity liability.
Consolidated net loss narrowed to ₹7.3 Cr from ₹23.1 Cr in the year-ago quarter.
👀 What to Watch
Monitor the resolution status of the USFDA warning letter for the Jigani facility and the recovery of profitability in the Crop Protection segment.
Hikal Q4 FY26 Revenue at ₹519 Cr; EBITDA Margin Recovers to 20.3% Amid Operational Turnaround
Hikal Limited reported a strong operational recovery in Q4 FY26 with revenue of ₹519 crores and EBITDA margins expanding to 20.3%. For the full year FY26, revenue stood at ₹1,713 crores, though the company reported a PBT loss of ₹79.3 crores primarily due to ₹85 crores in exceptional items related to labor codes and asset impairments. Both Pharma and Crop Protection segments showed significant sequential margin improvements in Q4, reaching 12% and 17.1% respectively. The company successfully reduced its debt-to-equity ratio to 0.56, signaling improved financial discipline.
Key Highlights
Q4 FY26 EBITDA margin improved to 20.3% compared to the annual average of 12.9%.
Pharma segment capacity utilization reached 80-85% with a target to increase DMF filings to 5-6 annually.
Crop Protection EBIT margin surged to 17.1% in Q4, indicating a recovery from global inventory corrections.
Exceptional items of ₹85 crores for the full year impacted the bottom line, including a ₹47 crore impairment in Q4.
Debt-to-equity ratio improved from 0.59 to 0.56 as of March 31, 2026.
👀 What to Watch
Investors should focus on the sharp sequential recovery in margins and management's guidance for a stronger FY27. The successful transition from remediation to growth, coupled with new R&D capabilities in HPAPI, makes Hikal a key watch for a cyclical turnaround.
Hikal Promoter B.N. Kalyani Declares Nil Encumbrance on 34.01% Stake for FY26
Promoter B.N. Kalyani has submitted an annual disclosure confirming that no shares held by the promoter group in Hikal Limited were pledged or encumbered during the financial year 2025-26. The declaration specifically covers 38,667,375 shares (31.36%) held by Kalyani Investment Company Limited and 3,273,375 shares (2.65%) held by BF Investment Limited. This filing is a mandatory annual requirement under Regulation 31(4) of SEBI (SAST) Regulations. It provides assurance to shareholders regarding the financial stability of the promoters and the lack of debt-related risks against their equity.
Key Highlights
Promoter B.N. Kalyani confirms zero encumbrance on shares held by KICL and BFIL for FY 2025-26.
Kalyani Investment Company Limited holds 38,667,375 shares, representing a 31.36% stake.
BF Investment Limited holds 3,273,375 shares, representing a 2.65% stake.
Total promoter group holding declared as unencumbered amounts to 34.01% of the company.
Disclosure is compliant with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 What to Watch
Investors should view this as a positive indicator of promoter financial health and transparency. No immediate action is required as this is a routine but important annual compliance filing.
Hikal Q4 FY26: Revenue at ₹519 Cr, EBITDA Margin Hits 20.3%, Final Dividend of 20% Announced
Hikal reported a sequential recovery in Q4 FY26 with revenues of ₹519 crore and a strong EBITDA margin of 20.3%, up from 17% in the previous quarter. Net profit for the quarter stood at ₹14 crore, significantly impacted by a one-time exceptional impairment charge of ₹47 crore related to manufacturing assets at Panoli. The Crop Protection segment showed robust momentum with 45% QoQ growth, while the Pharma business recovered from H1 regulatory headwinds with H2 revenues growing 60% over H1. The board has recommended a final dividend of 20%, bringing the total dividend for FY26 to 30%.
Key Highlights
Q4 Revenue reached ₹519 crore with EBITDA standing at ₹105 crore (20.3% margin).
Exceptional item of ₹47 crore recorded for impairment of Panoli manufacturing asset.
Crop Protection revenue grew 45% QoQ and 13% YoY to ₹228 crore.
Pharma business H2 FY26 revenue grew by 60% to ₹629 crore compared to H1 FY26.
Board approved a final dividend of 20% of Face Value, totaling 30% for the full year.
👀 What to Watch
Investors should focus on the operational turnaround and margin expansion which suggests the worst of the inventory cycle and regulatory hurdles is over. Monitor the commercialization of the new Personal Care and Specialty Chemicals segments in FY27 as potential growth drivers.
Hikal Q4 FY26: EBITDA Margins Recover to 20.3%; FY26 PAT Hit by ₹85 Cr Exceptional Items
Hikal reported a sequential recovery in Q4 FY26 with EBITDA margins rising to 20.3%, although revenue declined 6% YoY to ₹519 crore. The full-year FY26 performance was significantly impacted by exceptional charges totaling ₹85 crore related to new labor codes and asset impairments, resulting in a consolidated net loss of ₹49 crore compared to a ₹91 crore profit in FY25. Despite the annual loss, the company maintained its dividend policy, declaring a total dividend of 30% for the year. Management indicates that the worst of the cycle is over, with the Pharmaceutical segment showing a 60% revenue growth in H2 FY26 compared to H1 FY26.
Key Highlights
Q4 FY26 EBITDA margin improved to 20.3% from 16.8% in Q3 FY26, signaling operational recovery.
FY26 consolidated revenue fell 8% YoY to ₹1,713 crore, while EBITDA dropped 33% to ₹220 crore.
Exceptional items of ₹85 crore (₹38 crore labor code and ₹47 crore impairment) led to an annual net loss of ₹49 crore.
Pharmaceutical H2 FY26 revenue grew 60% over H1 FY26, recovering from earlier regulatory headwinds.
Total dividend for FY26 stands at 30%, including a final dividend recommendation of 20%.
👀 What to Watch
Investors should focus on the sequential margin improvement and the strong H2 recovery in the Pharma segment as signs of a turnaround. However, the impact of exceptional items and competitive pricing in Crop Protection warrants a cautious 'Watch' approach until FY27 growth stabilizes.
Hikal Concludes Revenue Recognition Probe with No Financial Impact; Appoints New Segment President
Hikal Limited has provided a final update on employee irregularities first disclosed in December 2025 regarding revenue recognition timing. An external fact-finding review determined that the issues were restricted to the preponement of genuine sales and have no impact on current or past financial results. The company has terminated the responsible employees and strengthened internal controls to prevent recurrence. Simultaneously, Hikal has appointed Mr. Ravi Khadabadi as President of Crop Protection & Specialty Chemicals to lead the segment's growth.
Key Highlights
External review confirmed irregularities were limited to preponement of genuine sales as of September 30, 2025.
Management concludes there is no financial impact on the company's current or previous reporting periods.
Responsible employees have been identified and relieved from their services at the company.
Mr. Ravi Khadabadi appointed as President - Crop Protection & Specialty Chemicals effective May 27, 2026.
👀 What to Watch
The closure of the investigation without financial restatements reduces governance risk for the company. Investors should now focus on the execution of the Crop Protection business under the new leadership.
Hikal FY26 Revenue Drops 8% to ₹17,126M; Reports Net Loss of ₹487M
Hikal Limited faced a difficult financial year ending March 2026, reporting a standalone net loss of ₹487 million compared to a profit of ₹909 million in FY25. The performance was severely impacted by exceptional items amounting to ₹851 million and a 7.9% decline in annual revenue to ₹17,126 million. However, the company showed signs of recovery in Q4 FY26 with a net profit of ₹146 million, compared to a loss in the preceding quarter. The board recommended a final dividend of ₹0.40 per share, maintaining some payout despite the annual loss.
Key Highlights
Annual revenue decreased by 7.9% YoY to ₹17,126 million in FY26 from ₹18,598 million.
Full-year net loss stood at ₹487 million, significantly impacted by ₹851 million in exceptional charges.
Q4 FY26 net profit was ₹146 million, a decline from ₹503 million in the same quarter last year.
Final dividend of ₹0.40 per share (20%) recommended, bringing the total FY26 dividend to ₹0.60.
Auditors flagged ongoing environmental litigation in the Supreme Court as an 'Emphasis of Matter'.
👀 What to Watch
The stock remains under pressure due to the significant annual loss and the legal overhang regarding environmental compliance. Investors should monitor the outcome of the Supreme Court proceedings and the company's ability to sustain the sequential recovery seen in Q4.
Hikal Reports FY26 Net Loss of ₹487 Million; Recommends ₹0.40 Final Dividend
Hikal Limited reported a weak set of results for FY 2025-26, swinging to a net loss of ₹487 million from a profit of ₹909 million in the previous year. Total revenue for the fiscal year declined by 7.9% to ₹17,126 million, primarily dragged down by exceptional items totaling ₹851 million. Despite the bottom-line pressure, the board has recommended a final dividend of ₹0.40 per share, bringing the total annual dividend to ₹0.60. The company also faces ongoing legal uncertainty regarding environmental compliance, which is currently pending before the Supreme Court.
Key Highlights
Annual revenue from operations decreased to ₹17,126 million in FY26 from ₹18,598 million in FY25.
Reported a consolidated net loss of ₹487 million for FY26 compared to a profit of ₹909 million in FY25.
Exceptional items of ₹851 million significantly impacted the full-year profitability.
Recommended a final dividend of ₹0.40 per share (20%), totaling ₹0.60 (30%) for the full year.
Auditors issued an 'Emphasis of Matter' regarding ongoing environmental litigation in the Supreme Court.
👀 What to Watch
Investors should remain cautious as the company has moved into a loss-making position and faces significant legal/regulatory overhang. Monitor the Supreme Court's decision on environmental compliance and the company's strategy to offset exceptional costs in upcoming quarters.
Hikal Reports FY26 Net Loss of ₹487 Million; Recommends ₹0.40 Final Dividend
Hikal Limited reported a weak set of results for FY26, swinging to a net loss of ₹487 million compared to a profit of ₹909 million in FY25. Annual revenue from operations declined by 7.9% to ₹17,126 million, significantly impacted by exceptional items totaling ₹851 million. Despite the full-year loss, the company reported a modest profit of ₹146 million in Q4 and declared a final dividend of ₹0.40 per share. Investors should be wary of the 'Emphasis of Matter' regarding ongoing environmental litigation currently pending in the Supreme Court.
Key Highlights
Recommended a final dividend of ₹0.40 per share (20%), bringing total FY26 dividend to ₹0.60 per share.
Annual revenue from operations fell to ₹17,126 million from ₹18,598 million in the previous fiscal year.
Reported a net loss of ₹487 million for FY26 against a net profit of ₹909 million in FY25.
Exceptional items of ₹851 million for the year severely impacted profitability.
Auditors highlighted legal uncertainty regarding environmental law compliance currently under Supreme Court review.
👀 What to Watch
Investors should exercise caution as the company has moved into a loss-making position for the full year and faces significant legal overhang from environmental investigations. Monitor for clarity on the Supreme Court ruling and signs of operational margin recovery in the coming quarters.
Hikal Reports FY26 Net Loss of ₹487M Amid Exceptional Items; Recommends ₹0.40 Final Dividend
Hikal Limited reported a weak performance for the fiscal year ended March 31, 2026, swinging to a standalone net loss of ₹487 million from a profit of ₹909 million in FY25. Annual revenue from operations declined by 7.9% year-on-year to ₹17,126 million, while the bottom line was heavily impacted by exceptional items totaling ₹851 million. Despite the losses, the board has recommended a final dividend of ₹0.40 per share, bringing the total dividend for the year to ₹0.60. The company also faces ongoing legal uncertainty regarding environmental compliance investigations currently pending in the Supreme Court.
Key Highlights
Standalone revenue for FY26 decreased by 7.9% to ₹17,126 million compared to ₹18,598 million in FY25.
Reported a standalone net loss of ₹487 million for the full year, compared to a net profit of ₹909 million in the previous fiscal.
Exceptional items of ₹851 million for FY26 significantly dragged down profitability.
Recommended a final dividend of 20% (₹0.40 per share), resulting in a total FY26 dividend of 30% (₹0.60 per share).
Appointed Mr. Sandip Parikh as an Additional Independent Director for a five-year term effective May 27, 2026.
👀 What to Watch
Investors should remain cautious as the company has turned loss-making at the net level due to significant exceptional charges and declining revenues. The ongoing environmental litigation in the Supreme Court remains a critical risk factor to monitor.
Hikal Q3 FY26 Revenue at ₹494 Cr; EBITDA Margins Recover to 16.8% Amid Pharma Turnaround
Hikal reported a recovery in Q3 FY26 with consolidated revenue of ₹494 crores and a significantly improved EBITDA margin of 16.8%, driven by the Pharmaceutical segment's return to operational normalcy. The company declared an interim dividend of ₹0.2 per share despite a reported loss caused by a one-time exceptional charge of ₹38 crores related to new labor code provisions. While the Pharma division saw revenue of ₹337 crores, the Crop Protection business at ₹157 crores continues to face pricing headwinds from Chinese overcapacity. Management expects a stronger Q4 as remediation efforts regarding US FDA audits are nearly complete and new capacities become operational.
Key Highlights
Q3 FY26 EBITDA stood at ₹83 crores with margins expanding to 16.8% compared to the 9M average of 9.6%
Pharmaceutical segment revenue reached ₹337 crores with a 12.3% EBIT margin as supply resumed post-remediation
A one-time exceptional charge of ₹38 crores for labor code compliance impacted the bottom line, though adjusted PBT grew 21%
Debt-equity ratio remains stable at 0.58 with ₹100 crore capex spent during the first nine months of FY26
Diversification into Personal Care is underway with 3-4 products expected to commercialize in FY27
👀 What to Watch
Investors should monitor the sustainability of the Pharma margin recovery and the successful ramp-up of the new specialty chemicals vertical in FY27. The stock is a 'Watch' for consistent execution following the completion of intensive regulatory remediation.
Hikal Declares ₹0.20 Interim Dividend; Sets Feb 17, 2026 as Record Date
Hikal Limited has declared an interim dividend of ₹0.20 per equity share (10% of face value) for the financial year 2025-26. The company has fixed February 17, 2026, as the record date to identify eligible shareholders, with the dividend payment scheduled to be completed by March 12, 2026. Investors are required to submit necessary tax documentation by February 18, 2026, to ensure appropriate Tax Deduction at Source (TDS) rates are applied. The standard TDS rate for resident shareholders with a valid PAN is 10%, provided the dividend exceeds ₹10,000.
Key Highlights
Interim dividend of ₹0.20 per equity share (10% on face value of ₹2) for FY 2025-26.
Record date for dividend eligibility is fixed as February 17, 2026.
Dividend payment to be processed on or before March 12, 2026.
TDS of 10% for residents with PAN; 20% for those without valid PAN or non-residents without treaty benefits.
Deadline for submitting tax exemption forms (15G/15H/TRC) is February 18, 2026.
👀 What to Watch
Investors should ensure their PAN and bank account details are updated with their Depository Participant by February 17. To avoid higher tax withholding, eligible shareholders must submit Form 15G/15H or Tax Residency Certificates to the company by the February 18 deadline.
